1 / 26

Adoption of Evidence-Based Practices in the CTN

Adoption of Evidence-Based Practices in the CTN. Paul M. Roman & Amanda J. Abraham University of Georgia Presentation at the NIDA Clinical Trials Network 10 th Anniversary Symposium, April 21, 2010 Albuquerque, New Mexico. UGA Platform Study of CTN Development and Impact (2001-present).

holly-adams
Download Presentation

Adoption of Evidence-Based Practices in the CTN

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Adoption of Evidence-Based Practices in the CTN Paul M. Roman & Amanda J. Abraham University of Georgia Presentation at the NIDA Clinical Trials Network 10th Anniversary Symposium, April 21, 2010 Albuquerque, New Mexico

  2. UGA Platform Study of CTN Development and Impact (2001-present) • Goal of this Presentation: To explore organization-level adoption, implementation, and discontinuation of evidence-based treatment practices (EBPs) • Two types of data analysis • Comparing the CTN to non-CTN programs • Change within the CTN over time • Adoption of: • Buprenorphine • Motivational incentives/contingency management • Alcohol pharmacotherapies

  3. Methodology • Face-to-face interviews with administrators and/or clinical directors of CTPs & mail/internet based surveys with counselors in CTPs • Three waves of data collection • Baseline (2002-2004) • 24 month follow-up • 48 month follow-up • Comparisons with 2 nationally representative samples: • Publicly funded programs (N=318) • Privately funded programs (N=345)

  4. Dissemination and the CTN • Dissemination of the results of CTN trials is a major part of the CTN mandate • This mandate has moved into prominence as the results of trials have been rolled out • Research Utilization Committee has mobilized much energy and in collaboration with ATTCs • CTN continues to develop and refine “Blending Products” and conduct “Blending Conferences”

  5. Dissemination and the CTN (2) • “Dissemination science” is complex and developed in the context of commercial marketing and at the level of groups and individuals • weak at the organizational level • What is the proper performance measure of “dissemination responsibility” of the CTN? • To put information about new treatment options in front of organizational consumers? • Moving innovations “all the way” to implementation?

  6. Dissemination in the ctn (3) • Implementation responsibility at the level of the individual provider • Providers are a complex mix of public, non-profit and for-profit organizations, based in diverse settings • Providers need strategic planning and a business orientation in using disseminated knowledge from the CTN in making implementation investments

  7. Adoption of Buprenorphine: Summary of Research Findings • 1. Study comparing adoption of buprenorphine in CTN and Non-CTN OTPs (Ducharme & Roman, 2009) • CTN affiliation was significantly associated with buprenorphine adoption • 2. Study examining adoption of buprenorphine over 2 year period in the CTN (Knudsen, Abraham, Johnson & Roman, 2009) • Baseline adoption of buprenorphine was positively associated with continued use at 24m follow-up • Buprenorphine protocol involvement was positively associated with adoption • Much of buprenorphine adoption at 24m follow-up was in programs without protocol experience

  8. Latest Findings from the Platform Study

  9. ADOPTION OF BUPRENORPHINE OVER A 4 YEAR PERIOD IN THE CTN Roman, Abraham, Rothrauff, & Knudsen. 2010. Journal of Substance Abuse Treatment, 38(4): S44-S52.

  10. Adoption of Buprenorphine over 4 year period in the CTN: Cross-sectional data

  11. Adoption of Buprenorphine over 4 year period in the CTN: Longitudinal data (N=129) 41%

  12. Barriers to Buprenorphine Adoption among non-adoptersRoman, Abraham, Rothrauff, & Knudsen. 2010. Journal of Substance Abuse Treatment, 38(4): S44-S52. • OTPs (N=21) • Cost associated with buprenorphine (23.8%) • Lack of access to a waivered physician (19.0%) • Non-OTPs, do not prescribe any medications (N=156) • 38 programs did not have access to prescribing staff, so adoption was not possible • Regulatory barriers (25.9%) • Inconsistent with treatment philosophy, better alternatives available (18.5%) • Liability issues (18.5%) • Non-OTPs, prescribe other medications (N=40) • Cost of buprenorphine (17.5%) • Prescriber did not have a buprenorphine waiver (17.5%) • Current medical personnel prefer not to prescribe buprenorphine (10%)

  13. Adoption of Motivational Incentives Over 4 Year Period in the CTN Roman, Abraham, Rothrauff, & Knudsen. 2010. Journal of Substance Abuse Treatment, 38(4): S44-S52.

  14. Adoption of Motivational Incentives over 4 year period in the CTN: Cross-sectional data

  15. Adoption of Motivational Incentives over 4 year period in the CTN: Longitudinal data (N=124) 61%

  16. Barriers to MI/CM adoption among non-adoptersRoman, Abraham, Rothrauff, & Knudsen. 2010. Journal of Substance Abuse Treatment, 38(4): S44-S52. • Cost associated with implementation (32.5%) • Lack of compatibility with program’s philosophy(15.4%) • Logistical issues such as competing demands, short length of stay, lack of a developed protocol for implementing MI/CM (11.4%) • Perceived ineffectiveness of MI/CM with the program’s population (10.6%)

  17. Adoption of Alcohol Pharmacotherapies in CTN and Non-CTN Programs Abraham, Knudsen, Rothrauff, & Roman. 2010. Journal of Substance Abuse Treatment, 38(3): 275-283.

  18. Data • Pooled sample of publicly funded CTN and non-CTN programs • 127 CTN programs • 147 Non-CTN programs • Utilized data collected at baseline (2002-2004) and 24-month follow-up

  19. Adoption of tablet naltrexone for alcohol dependence *Adoption of tablet naltrexone increased by 6.3% over time in the CTN and did not change in non-CTN programs.

  20. Early Adoption of acamprosate

  21. Key FindingsAbraham, Knudsen, Rothrauff, & Roman. 2010. Journal of Substance Abuse Treatment, 38(3): 275-283. • CTN participation was not a significant predictor of tablet naltrexone adoption at baseline • At 24-month follow-up, CTN programs were three times more likely than non-CTN programs to adopt tablet naltrexone • net of program structure and culture, environmental scanning, membership in a provider association, and administrator education • CTN programs were three timesmore likely than non-CTN programs to adopt acamprosate in 2006 • net of program culture, environmental scanning, membership in a provider association, and administrator education

  22. Summary of platform study Findings • Successful adoption of buprenorphine in the CTN • Greater adoption of EBPs in CTN versus non-CTN treatment programs • Overall importance of research network in promoting adoption of EBPs

  23. Acknowledgements We gratefully acknowledge the research support of the National Institute on Drug Abuse (Grant No. R01DA14482, R21DA020028, and R01DA013110), and the participation of community treatment programs affiliated with the CTN in this research study.

  24. Availability of physicians • 27% of CTN programs do not have a physician on staff/contract • Of programs with physicians: • 54% of non-OTP CTN programs with a physician on staff/contract do not prescribe alcohol pharmacotherapies • 23% of CTN programs do not prescribe buprenorphine

  25. Availability of physicians: Comparisons to the public and private sector • 27% of CTN programs do not have a prescribing physician on staff/contract • 23% of private programs do not have a prescribing physician on staff/contract • 38% of public programs do not have a prescribing physician on staff/contract

  26. Prescription of pharmacotherapies: Comparison to the public and private sectors • Of programs with a physician: • 41% of private programs with access to a physician do not prescribe alcohol pharmacotherapies and 49% do not prescribe buprenorphine • 82%of public programs with access to a physician do not prescribe alcohol pharmacotherapies and 67% do not prescribe buprenorphine • 54% of non-OTP CTNprograms with access to a physician do not prescribe alcohol pharmacotherapies and 23%of CTN programs do not prescribe buprenorphine

More Related